Dianthus Therapeutics Inc (NAS:DNTH)
$ 21.54 0.91 (4.4%) Market Cap: 632.19 Mil Enterprise Value: 231.00 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 22/100

Magenta Therapeutics Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / 04:00PM GMT
Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst

© -

Hi, everyone, and welcome to this session at the 31st Annual Credit Suisse Healthcare Conference. I'm Judah Frommer, one of the senior biotech analysts here at CS. We're very excited to have Magenta Therapeutics presenting. And we have Jason Gardner, the CEO, President and Co-Founder. Jason, I'll pass it over to you now.

Jason Gardner
Magenta Therapeutics, Inc. - Co-Founder, CEO, President & Director

Thank you, Judah. Good morning, everybody. And thank you also to the Credit Suisse team for the opportunity to present today about -- on Magenta Therapeutics. I will share my screen and a slide deck that I will use today, and that should be visible full size. So we're going to talk today about where we are at Magenta Therapeutics with our progress in transforming the field of stem cell transplant. Big area, big opportunity, ripe for innovation. We're going to talk about our antibody drug conjugate programs, and in particular, focus on our clinical progress and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot